Issue Date: March 19, 2018
Prevail raises big money for Parkinson’s
In another impressive first round of funding for a New York City biotech firm, Prevail Therapeutics has raised a $75 million series A. Prevail launched with seed funding last year to develop adeno-associated virus (AAV)-based gene therapies for neurodegenerative diseases related to lysosomal dysfunction, including a subset of Parkinson’s disease. Prevail will use Regenxbio’s AAV9 vector, which targets the nervous system.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society